Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 8/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.42 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4331911 | 1.00 | P2RX7 (0.43) | P2RX7ALDH1A1CYP1A2CYP2D6AMY1A | |
| SCHEMBL4323675 | 1.00 | P2RX7 (0.43) | P2RX7ALDH1A1CYP1A2CYP2D6AMY1A | |
| SCHEMBL4324992 | 0.74 | PDCD1LG2 (0.46) | ALDH1A1CYP1A2CYP2D6PDCD1LG2CD274 | |
| SCHEMBL4330343 | 0.73 | CYP1A2 (0.47) | ALDH1A1CYP1A2CYP2D6AMY1AKMT2A | |
| SCHEMBL4332509 | 0.73 | CYP1A2 (0.47) | ALDH1A1CYP1A2CYP2D6AMY1AKMT2A | |
| SCHEMBL4330351 | 0.73 | CYP1A2 (0.47) | ALDH1A1CYP1A2CYP2D6AMY1AKMT2A | |
| SCHEMBL22345799 | 0.70 | TRPV3 (0.49) | ALDH1A1CYP1A2CYP2D6AMY1APDCD1LG2 | |
| SCHEMBL22345802 | 0.70 | TRPV3 (0.49) | ALDH1A1CYP1A2CYP2D6AMY1APDCD1LG2 | |
| SCHEMBL30850022 | 0.70 | TRPV3 (0.49) | ALDH1A1CYP1A2CYP2D6AMY1APDCD1LG2 | |
| SCHEMBL26618708 | 0.70 | TRPV3 (0.49) | ALDH1A1CYP1A2CYP2D6AMY1APDCD1LG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101312965-B | Morpholine type cinnamamide compound | EISAI R&D MAN CO LTD | 2011-07-20 | — | — | CN | disclosed |
| US-7618960-B2 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-17 | — | — | US | disclosed |
| CN-101312965-A | Morpholine type cinnamamide compound | EISAI R&D MAN CO LTD (JP) | 2008-11-26 | — | — | CN | disclosed |
| EP-1953154-A1 | MORPHOLINE TYPE CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070117798-A1 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117798-A1 | Morpholine type cinnamide compound | MLX, XDH, NOX4 | P2RX7 397/4885ALDH1A1 785/4885CYP1A2 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.